City of Hope shared on LinkedIn:
“In a new study published in Nature, City of Hope researchers and collaborators (Memorial Sloan Kettering Cancer Center and Seres Therapeutics) pioneered a first-of-its-kind investigational therapy that harnesses the microbiome to help prevent dangerous bloodstream infections in patients receiving donor stem cell transplants for blood cancers.
The findings demonstrate a potential new approach to addressing a serious complication of donor stem cell transplantation and underscores the potential of the microbiome in cancer care.
Learn more about the research led by Marcel van den Brink.”
Title: A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial
Authors: Doris M. Ponce, Zachariah DeFilipp, Christopher B. Ford, Bina Tejura, Mary-Jane Lombardo, David I. Lichter, Meghan Chafee, Satyajit Kosuri, Nandita Khera, Hemant S. Murthy, Karamjeet S. Sandhu, David N. Fredricks, Tessa Andermann, Rajneesh Nath, Kelly Brady, Brooke R. Hasson, Emily Walsh, Nathan Hicks, Jonathan U. Peled, Lisa von Moltke, Matthew R. Henn, Marcel R. M. van den Brink, Dennis M. Walling, the SER-155-001 Study Team
Read the Full Article on Nature Medicine.
You can also read: BPDCN: Frontline Tagraxofusp Produces Responses, but Durable Remission Tracks With Transplant
